Report on the world-first catheter delivery of stem-cell cardiac therapy and early clinical progress in treating severe heart failure.
Key Takeaways
- We are open to conversations with prospective partners and investors who share our vision
- Study marks the world’s first clinical trial to administer iPSC-derived cardiomyocyte spheroids by catheter
- Postoperative course was generally uneventful and the patient has been discharged